A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma
OP-701
Phase 1 other active
Quick answer
A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma for Recurrent glioblastoma is a Phase 1 program (other) at Oncopeptides AB (publ) with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Oncopeptides AB (publ)
- Indication
- Recurrent glioblastoma
- Phase
- Phase 1
- Modality
- other
- Status
- active